Lawrence Karsh, MD, FACS

Lawrence I Karsh MD FACS is the Director of Research, attending Urologist, and a co-founder of The Urology Center of Colorado. Dr. Karsh has served as the Principal Investigator in over 260 clinical trials. He is an active member of the AUA,SUO,ASCO,ESMO,SBUR,BCAN and ACRP. In addition,he reviews articles for leading Urology journals. He served on the board of the SUO Clinical Trials Consortium from 2010-2020 and is currently co-chairman of the Advanced Therapeutics Clinic at TUCC.

Dr. Karsh did his general surgical training at the University of Colorado Health Sciences Center and completed his urology residency at Brigham and Womens/Harvard Medical School.

Financial relationships

Attribution:
Self
Type of financial relationship:
Consultant or Advisor (Oncology)
Ineligible company:
Clovis
Mitigation strategy:
Peer review
Date reviewed:
09/20/2022
Attribution:
Self
Type of financial relationship:
Scientific Study or Trial (Oncology)
Ineligible company:
Exact Sciences
Mitigation strategy:
Peer review
Date reviewed:
09/20/2022
Attribution:
Self
Type of financial relationship:
Consultant or Advisor (Oncology)
Ineligible company:
Tolmar
Mitigation strategy:
Peer review
Date reviewed:
09/20/2022
Attribution:
Self
Type of financial relationship:
Scientific Study or Trial (Oncology)
Ineligible company:
Exelexis
Mitigation strategy:
Peer review
Date reviewed:
09/20/2022
Attribution:
Self
Type of financial relationship:
Scientific Study or Trial (Oncology)
Ineligible company:
Epizyme
Mitigation strategy:
Peer review
Date reviewed:
09/20/2022
Attribution:
Self
Type of financial relationship:
Consultant or Advisor (Oncology)
Ineligible company:
Sesen
Mitigation strategy:
Peer review
Date reviewed:
09/20/2022
Attribution:
Self
Type of financial relationship:
Consultant or Advisor (Oncology)
Ineligible company:
Merck
Mitigation strategy:
Peer review
Date reviewed:
09/20/2022
Attribution:
Self
Type of financial relationship:
Consultant or Advisor (Oncology)
Ineligible company:
Kiadis
Mitigation strategy:
Peer review
Date reviewed:
09/20/2022
Attribution:
Self
Type of financial relationship:
Scientific Study or Trial (Oncology)
Ineligible company:
Tavanta
Mitigation strategy:
Peer review
Date reviewed:
09/20/2022
Attribution:
Self
Type of financial relationship:
Consultant or Advisor (Oncology)
Ineligible company:
Boston Scientific
Mitigation strategy:
Divest
Date reviewed:
09/20/2022

Pages

Return to 2022 AUA Annual Meeting Highlights: Prostate Cancer

American Urological Association

Bookmark/Search this post

Lawrence Karsh, MD, FACS

Financial relationships

Pages

You are here

Lawrence Karsh, MD, FACS

Financial relationships

Pages